CPC to Senators: Halt Confirmation of Azar until Investigation into His Role in Illegal Price Gouging is Complete
November 28, 2017
Today, Congressional Progressive Caucus Co-Chairs Rep. Raúl M. Grijalva (D-AZ) and Rep. Mark Pocan (D-WI), along with CPC Healthcare Taskforce Chair Rep. Jan Schakowsky (D-IL), sent the attached letter to the Senate Health, Education, Labor & Pensions Committee and the Senate Finance Committee. The letter expresses the Caucus' strong opposition to the nomination of President Trump's pharmaceutical executive nominee, Alex Azar, to be the next Secretary of the U.S. Department of Health and Human Services due to ongoing state investigations into Azar's potential involvement in dangerous drug-price spikes while serving as CEO of Eli Lilly.